American Academy of Pediatrics. Committee on Fetus and Newborn. Use of inhaled nitric oxide.
Approval of inhaled nitric oxide by the US Food and Drug Administration for hypoxic respiratory failure of the term and near-term newborn provides an important new therapy for this serious condition. This statement addresses the conditions under which inhaled nitric oxide should be administered to the neonate with hypoxic respiratory failure.
D000280:Administration, Inhalation; D001238:Asphyxia Neonatorum / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D015199:Extracorporeal Membrane Oxygenation; D006801:Humans; D000860:Hypoxia / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D007231:Infant, Newborn; D009569:Nitric Oxide / Q000008:administration & dosage*; D012127:Respiratory Distress Syndrome, Newborn / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D012131:Respiratory Insufficiency / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome
D009569:Nitric Oxide